Article Text

PDF
Botulinum toxin A during pregnancy: a survey of treating physicians
  1. J C Morgan1,
  2. S S Iyer1,
  3. E T Moser1,
  4. C Singer2,
  5. K D Sethi1
  1. 1Movement Disorders Program, Department of Neurology, Medical College of Georgia, Augusta, GA, USA
  2. 2Department of Neurology, University of Miami School of Medicine, Miami, FL, USA
  1. Correspondence to:
 Dr J C Morgan
 Movement Disorders Program, Department of Neurology, Medical College of Georgia, 1429 Harper Street, HF-1121, Augusta, GA, USA 30912; jmorgan{at}mcg.edu

Abstract

Botulinum toxin A (btxA) is widely used for cosmetic purposes, headaches, dystonia, spasticity, pain and other on and off label uses. Despite the widespread use of btxA in women of childbearing potential, there are few data on the effects of this drug on pregnant women and the fetus. The goal of this study was to survey physicians who use btxA, to determine their experience with pregnant women. We surveyed 900 physicians who used commercially available btxA. The questionnaire asked treating physicians if they had knowingly or unknowingly injected pregnant women and what was the outcome of each pregnancy. In total, 396 physicians (44%) returned questionnaires, of whom only 12 physicians reported injecting pregnant women with btxA. Sixteen pregnant women were injected, mostly in the first trimester, and only one patient, who had prior spontaneous abortions, suffered a miscarriage. Another woman had a therapeutic abortion. All other pregnancies went to term and there were no fetal malformations. Based on this limited survey of treating physicians in the USA, btxA appears to be relatively safe for both expectant mother and fetus. We need further data, however, and we would recommend that physicians and patients carefully consider the risks and benefits before using btxA in pregnant women.

Statistics from Altmetric.com

Footnotes

  • This study was supported in part by Allergan. As authors, we initiated this study and designed the questionnaire. We had full access to all of the data and performed our own analysis of the data. Drs. Singer and Sethi have received grant support and speaking honoraria from Allergan.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.